A compared with BIO: revenue, margins and what each company keeps, and the suppliers and customers both name

AAgilent Technologies, Inc.

Mkt capRevenueRevenue

BIOBio-Rad Laboratories, Inc.

Mkt capRevenueRevenue

Compare

AAgilent Technologies, Inc.

BIOBio-Rad Laboratories, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±7.9%▲+1.68%×0.22

Q2 FY26±7.7%▲+16.87%×2.19

Q1 FY26±6.4%▼−3.01%×0.47

Nov 25 '25±6.5%▲+2.34%×0.35

BIO1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+4.50%—

= impliedA realized, solidBIO realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

AAgilent Technologies, Inc.

175.74▲+2.18%· post 175.74· delayed

Mkt cap$48.5BRevenue$1.9BQ3 FY26Revenue$6.9BFY25

BIOBio-Rad Laboratories, Inc.

373.48▲+2.00%· post 373.48· delayed

After hoursNov 3 '26delayed

Mkt cap$9.8BRevenue$651MQ2 FY26Revenue$2.6BFY25

Compare

After hoursNov 3 '26delayed

AAgilent Technologies, Inc.

BIOBio-Rad Laboratories, Inc.

175.74▲+2.18%post 175.74delayed

Price

373.48▲+2.00%post 373.48delayed

$48.5B

Mkt cap

$9.8B

Q3 FY26$1.9B

Revenue

$651MQ2 FY26

FY25$6.9B

Revenue

$2.6BFY25

A175.74▲+2.18%vsBIO373.48▲+2.00%After hoursNov 3 '26delayed